The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects

July 20, 2007 updated by: Tufts University
The purpose of this study is to determine whether cinacalcet will increase gastric acid secretion in healthy volunteers.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The calcium sensing receptor (CaSR) was originally found on parathyroid and renal cells and more recently it has been identified on cells that regulate gastric acid secretion (G cells and parietal cells). However, its role in regulating acid secretion in humans is completely unknown and is of potential importance because an acid environment in the stomach enhances intestinal calcium absorption. In this pilot project, we will stimulate the CaSR with a CaSR-agonist called cinacalcet. Our hypothesis is that activation of the CaSR will in turn increase gastric acid production in healthy volunteers.

Study Type

Interventional

Enrollment (Actual)

17

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Massachusetts
      • Boston, Massachusetts, United States, 02111
        • Human Nutrition Research Center on Aging at Tufts University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy ambulatory men and postmenopausal women
  • Age 45 to 70
  • Avoid alcohol, antacids, H2 blockers, proton pump inhibitors, or antihistamines during the study.

Exclusion Criteria:

  • Ionized Ca++ level <4.39 mg/dl or >5.02 mg/dl (normal reference range 4.18- 5.02).
  • 24-hour UCa++ excretion >350 mg.
  • Cr >1.3.
  • AST/ALT values >10% beyond reference range.
  • Hgb level <11.7 g/dl in women and <13.2 g/dl in men.
  • MCV level >102 UM3.
  • Basal acid output >5 mEq/h in men and >3.8 mEq/h in women.
  • Basal acid output <1 mEq/h in men and <0.2 mEq/h in women.
  • Age <45 or >70.
  • Premenopausal or <1 year post-menopause.
  • Individuals following vegan diets.
  • Current EtOH abuse.
  • Lidocaine allergy. Medications
  • Antacids
  • H2 blockers
  • Proton pump inhibitors
  • Carafate
  • Anticholinergic agents (i.e. TCA)
  • Cholinergic agents
  • Antihistamines in the last 3 weeks
  • Cogentin
  • Adrenergic blockers
  • Thiazide diuretics
  • Antiplatelet drugs
  • Oral and Inhaled Glucocorticoids
  • Bisphosphonates
  • Raloxifene, Tamoxifen
  • Tobacco
  • EtOH during study
  • rPTH
  • Calcitonin
  • Ketoconazole/Itraconazole
  • Calcitriol
  • Paricalcitol
  • Drisdol, Ergocalciferol
  • Phosphate binders
  • Anticoagulant
  • Erythromycin
  • Hormone replacement therapy except vaginal estrogen creams

Exclusion Diseases

  • Achlorhydria
  • Pernicious anemia
  • Zollinger Ellison syndrome
  • Congestive heart failure
  • Esophageal strictures or motility problems
  • History of a GI bleed
  • Prior upper GI surgery
  • Malabsorption
  • History of GI malignancy
  • GERD, gastritis, duodenitis
  • Active peptic ulcer disease
  • Gallbladder disease
  • Liver disease
  • Pancreatitis
  • Current kidney stone
  • Renal disease
  • Current hypoparathyroidism or hyperparathyroidism
  • Moderate to Severe coronary artery disease
  • Aortic aneurysm
  • Seizure disorder
  • Current Arrhythmia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Compare change in gastric acid output in response to an 11-day course of daily cinacalcet or placebo in subjects on a fixed protein metabolic diet.
Time Frame: 11 days
11 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Compare serum gastrin levels in subjects before and after an 11-day course of cinacalcet or placebo and on a fixed protein metabolic diet.
Time Frame: 11 days
11 days
Compare 24-hour urinary calcium excretion before and after an 11-day course of cinacalcet or placebo and on a fixed protein metabolic diet.
Time Frame: 11 days
11 days
Compare serum IGF-1 levels before and after an 11-day course of cinacalcet or placebo and on a fixed protein metabolic diet.
Time Frame: 11 days
11 days
Compare change in urinary magnesium excretion in response to an 11-day course of daily cinacalcet or placebo in subjects on a fixed protein metabolic diet.
Time Frame: 11 days
11 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tufts University

Investigators

  • Principal Investigator: Bess Dawson-Hughes, MD, Human Nutrition Research Center on Aging at Tufts University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2006

Primary Completion

December 7, 2022

Study Completion (Actual)

March 1, 2007

Study Registration Dates

First Submitted

June 12, 2006

First Submitted That Met QC Criteria

June 12, 2006

First Posted (Estimate)

June 14, 2006

Study Record Updates

Last Update Posted (Estimate)

July 23, 2007

Last Update Submitted That Met QC Criteria

July 20, 2007

Last Verified

June 1, 2007

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2455

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on cinacalcet

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe